about
Online self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefitsImmune response CC chemokines CCL2 and CCL5 are associated with pulmonary sarcoidosisLack of FGF23 response to acute changes in serum calcium and PTH in humans.Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cellsFinal trial report of sentinel-node biopsy versus nodal observation in melanoma.Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patientsValidity of the walking scale for spinal cord injury and other domains of function in a multicenter clinical trial.International randomized clinical trial, stroke inpatient rehabilitation with reinforcement of walking speed (SIRROWS), improves outcomes.The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanomaMethods for a randomized trial of weight-supported treadmill training versus conventional training for walking during inpatient rehabilitation after incomplete traumatic spinal cord injury.The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I).Longitudinal data analysis with non-ignorable missing dataSentinel-node biopsy or nodal observation in melanoma.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesPhase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPDLung cancer chemoprevention with celecoxib in former smokers.Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.Early skeletal and biochemical alterations in pediatric chronic kidney disease.Comparison of the variability of the annual rates of change in FEV₁ determined from serial measurements of the pre- versus post-bronchodilator FEV₁ over 5 years in mild to moderate COPD: results of the lung health study.Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) TrialThe skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study.A controlled trial of protein enrichment of meal replacements for weight reduction with retention of lean body mass.A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study.Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality.Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma.Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.GLP-1-based therapy for diabetes: what you do not know can hurt you.Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.Growth hormone and the skeleton in pediatric renal allograft recipients.Inhibition of fibroblast growth factors by green tea.
P50
Q28544012-83aa8d97-4c5b-63a3-4478-b096d148dd46Q30432636-f4227345-4612-2062-13a6-c7ba9e808cdbQ33570120-8963bc7d-49e7-75ce-6b4d-5b2fa6d9b8faQ33627550-5e959d2d-421f-878c-7404-26e3a037ca11Q33760173-352ade7e-4375-a260-1172-98309bcc5d6eQ33797051-87ac42a3-4760-eb10-6867-7956c7f1d11cQ33842578-4301892c-4683-0491-b603-ba7259235b46Q33904241-7ddf2eed-4a4a-2099-5373-faafdba91724Q33984825-3f4cde0e-425e-194a-b5d1-9357f7c0954aQ33997362-480cb383-4a49-c67e-295f-004778d2f937Q34121782-417a1c7c-449d-ebc2-8727-633c94e5b3c3Q34172974-7c22d091-437b-9b84-c205-5488da573d85Q34268361-f9e290af-4090-85fa-d2bf-5ef16510960cQ34283741-c6e6588f-4bdb-7b4b-9b07-4c19052ea085Q34571347-020dc527-4307-b91b-7290-44f096fcce7bQ34627077-d4974b56-47f4-e8fb-0121-cacd42ada511Q34679133-7a788572-4114-acc3-b2b0-f06132830ea3Q34823949-9ad6681b-49f0-cc1c-2b41-fd1eb9db30ddQ35156358-09d74e83-418f-61b4-df2f-999d913ecb61Q35242200-b8fb769f-4d55-9708-67d9-c50bbed893d3Q35692418-4fae6cac-4784-168a-656a-51eaedf5c2fdQ36226565-b978d0cf-4c50-6af7-306f-fae549a698f3Q36476468-7f3e1c6a-43c8-88e0-0a85-085d6c561a7aQ36810441-5b1ac82d-481f-4364-1491-37ec85b29d7cQ36810768-136d868d-46d8-b066-4923-44634b9408b3Q36882078-3a2b8563-4427-f1e7-0f51-88f2ddfc5dd3Q36942123-56f4f9ec-48c8-399d-3927-0823d8411da1Q36976489-2d53b491-4789-274c-294e-87348105b8adQ37069999-b7d9ce0c-40df-76ff-90f2-f14839db183aQ37412005-98441992-4c48-9c96-900f-91b89a5db0faQ37421246-ffe9c034-4578-1d4e-3134-91ba1ff2e76aQ37616717-969d46c7-42cb-790f-fee1-2f7ae2e93591Q37767492-874836d3-42ea-818e-08c3-1f2ce74228faQ38698659-dba3b75b-44ce-59e7-cd7e-ec5675a6032cQ38854180-52be6a8d-4005-2ac5-d3ee-a5374775460bQ41752437-a8a1de10-42db-dfd5-221c-a132a49e90baQ42933615-44a6d18b-4cd1-e630-b977-d2a355706708Q43022171-b9d5ae48-45b0-54e0-726c-1c0e7b1373fbQ44013473-81a4f71f-4ccd-36b3-d86a-9595abb88b5bQ44094715-a3679a72-404d-040a-0585-96860ff0e8ca
P50
description
Amerikaans onderzoeker
@nl
chercheur et biostatisticien américain
@fr
name
Robert Elashoff
@de
Robert Elashoff
@en
Robert Elashoff
@es
Robert Elashoff
@fr
Robert Elashoff
@nl
Robert Elashoff
@pt
Robert Elashoff
@sv
type
label
Robert Elashoff
@de
Robert Elashoff
@en
Robert Elashoff
@es
Robert Elashoff
@fr
Robert Elashoff
@nl
Robert Elashoff
@pt
Robert Elashoff
@sv
altLabel
Robert M Elashoff
@en
Robert M. Elashoff
@de
Robert M. Elashoff
@en
Robert M. Elashoff
@es
Robert M. Elashoff
@fr
Robert M. Elashoff
@pt
Robert M. Elashoff
@sv
Robert Myles Elashoff
@de
Robert Myles Elashoff
@en
Robert Myles Elashoff
@es
prefLabel
Robert Elashoff
@de
Robert Elashoff
@en
Robert Elashoff
@es
Robert Elashoff
@fr
Robert Elashoff
@nl
Robert Elashoff
@pt
Robert Elashoff
@sv
P1006
P214
P227
P244
P1006
P106
P21
P213
0000 0000 3508 6909
P214
P227
1126665886
P244
P31
P734
P7859
lccn-n85082362